Richard Aldrich

Filings by Richard Aldrich span 6 companies, the busiest being Tempest Therapeutics, Inc., Concert Pharmaceuticals, Inc. and Verastem, Inc. The record holds 142 filings, for trades running from 29 May 2007 to 6 March 2023.

In open-market terms, that means 62 purchases worth €22.1M on one side and 26 sales worth €2.7M on the other. Purchases outweigh sales by €19.4M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 20 share grants and 5 option exercises.

In size, the median ticket on the buying side is €37k. 26 out of 26 purchases came within 30 days of a purchase by at least one other insider of the same company. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

The latest filing, published on 6 March 2023, reports a transaction in Concert Pharmaceuticals, Inc. The most recent open-market purchase was published on 6 June 2022, 1,601 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.